122 related articles for article (PubMed ID: 34612509)
1. Characterisation of agonist signalling profiles and agonist-dependent antagonism at PACAP-responsive receptors: Implications for drug discovery.
Tasma Z; Siow A; Harris PWR; Brimble MA; Hay DL; Walker CS
Br J Pharmacol; 2022 Feb; 179(3):435-453. PubMed ID: 34612509
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of PACAP and VIP receptors in the spinal cord highlights the importance of the PAC
Tasma Z; Rees TA; Guo S; Tan S; O'Carroll SJ; Faull RLM; Curtis MA; Christensen SL; Hay DL; Walker CS
Br J Pharmacol; 2024 Apr; ():. PubMed ID: 38616050
[TBL] [Abstract][Full Text] [Related]
3. Early Alterations of PACAP and VIP Expression in the Female Rat Brain Following Spinal Cord Injury.
Broome ST; Mandwie M; Gorrie CA; Musumeci G; Marzagalli R; Castorina A
J Mol Neurosci; 2023 Oct; 73(9-10):724-737. PubMed ID: 37646964
[TBL] [Abstract][Full Text] [Related]
4. Novel Fluorescently Labeled PACAP and VIP Highlight Differences between Peptide Internalization and Receptor Pharmacology.
Alexander TI; Tasma Z; Siow A; Rees TA; Brimble MA; Harris PWR; Hay DL; Walker CS
ACS Pharmacol Transl Sci; 2023 Jan; 6(1):52-64. PubMed ID: 36654758
[TBL] [Abstract][Full Text] [Related]
5. Domains determining agonist selectivity in chimaeric VIP2 (VPAC2)/PACAP (PAC1) receptors.
Lutz EM; MacKenzie CJ; Johnson M; West K; Morrow JA; Harmar AJ; Mitchell R
Br J Pharmacol; 1999 Oct; 128(4):934-40. PubMed ID: 10556928
[TBL] [Abstract][Full Text] [Related]
6. Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors.
Lu J; Piper SJ; Zhao P; Miller LJ; Wootten D; Sexton PM
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897648
[TBL] [Abstract][Full Text] [Related]
7. Development of a New Enzyme-Linked Immunosorbent Assay (ELISA) for Measuring the Content of PACAP in Mammalian Tissue and Plasma.
Obara EAA; Georg B; Hannibal J
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894782
[TBL] [Abstract][Full Text] [Related]
8. From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment.
Tanaka M; Szabó Á; Körtési T; Szok D; Tajti J; Vécsei L
Cells; 2023 Nov; 12(22):. PubMed ID: 37998384
[TBL] [Abstract][Full Text] [Related]
9. PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance.
Jamen F; Persson K; Bertrand G; Rodriguez-Henche N; Puech R; Bockaert J; Ahrén B; Brabet P
J Clin Invest; 2000 May; 105(9):1307-15. PubMed ID: 10792006
[TBL] [Abstract][Full Text] [Related]
10. PACAP key interactions with PAC1, VPAC1, and VPAC2 identified by molecular dynamics simulations.
Meireles FATP; Antunes D; Temerozo JR; Bou-Habib DC; Caffarena ER
J Biomol Struct Dyn; 2024 Apr; 42(6):3128-3144. PubMed ID: 37216328
[TBL] [Abstract][Full Text] [Related]
11. Pituitary adenylate cyclase activating peptide (PACAP) participates in adipogenesis by activating ERK signaling pathway.
Arsenijevic T; Gregoire F; Chiadak J; Courtequisse E; Bolaky N; Perret J; Delporte C
PLoS One; 2013; 8(9):e72607. PubMed ID: 24039785
[TBL] [Abstract][Full Text] [Related]
12. PACAP-38 related modulation of the cranial parasympathetic projection: A novel mechanism and therapeutic target in severe primary headache.
Akerman S; Goadsby PJ; Romero-Reyes M
Br J Pharmacol; 2024 Feb; 181(3):480-494. PubMed ID: 37706270
[TBL] [Abstract][Full Text] [Related]
13. The pituitary adenylate cyclase activating polypeptide type 1 receptor (PAC1-R) is expressed on gastric ECL cells: evidence by immunocytochemistry and RT-PCR.
Zeng N; Kang T; Lyu RM; Wong H; Wen Y; Walsh JH; Sachs G; Pisegna JR
Ann N Y Acad Sci; 1998 Dec; 865():147-56. PubMed ID: 9928007
[TBL] [Abstract][Full Text] [Related]
14. Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS.
Sun C; Song D; Davis-Taber RA; Barrett LW; Scott VE; Richardson PL; Pereda-Lopez A; Uchic ME; Solomon LR; Lake MR; Walter KA; Hajduk PJ; Olejniczak ET
Proc Natl Acad Sci U S A; 2007 May; 104(19):7875-80. PubMed ID: 17470806
[TBL] [Abstract][Full Text] [Related]
15. Potential Crosstalk between the PACAP/VIP Neuropeptide System and Endoplasmic Reticulum Stress-Relevance to Multiple Sclerosis Pathophysiology.
Withana M; Castorina A
Cells; 2023 Nov; 12(22):. PubMed ID: 37998368
[TBL] [Abstract][Full Text] [Related]
16. Gene deletion of the PACAP/VIP receptor, VPAC2R, alters glycemic responses during metabolic and psychogenic stress in adult female mice.
Kozlova EV; Bishay AE; Denys ME; Chinthirla BD; Valdez MC; Spurgin KA; Krum JM; Basappa KR; Currás-Collazo MC
J Neuroendocrinol; 2023 Nov; 35(11):e13354. PubMed ID: 37946684
[TBL] [Abstract][Full Text] [Related]
17. Impact Assessment of Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) and Hemostatic Sponge on Vascular Anastomosis Regeneration in Rats.
Fazekas LA; Szabo B; Szegeczki V; Filler C; Varga A; Godo ZA; Toth G; Reglodi D; Juhasz T; Nemeth N
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069018
[TBL] [Abstract][Full Text] [Related]
18. Increased pituitary adenylate cyclase-activating peptide genes expression in the prefrontal cortex in schizophrenia in relation to suicide.
Slabe Z; Balesar RA; Verwer RWH; Drevenšek G; Swaab DF
Front Mol Neurosci; 2023; 16():1277958. PubMed ID: 38025265
[TBL] [Abstract][Full Text] [Related]
19. PACAP induces signaling and stimulation of 5-hydroxytryptamine release and growth in neuroendocrine tumor cells.
Germano PM; Lieu SN; Xue J; Cooke HJ; Christofi FL; Lu Y; Pisegna JR
J Mol Neurosci; 2009 Nov; 39(3):391-401. PubMed ID: 19701709
[TBL] [Abstract][Full Text] [Related]
20. A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases.
Martínez C; Juarranz Y; Gutiérrez-Cañas I; Carrión M; Pérez-García S; Villanueva-Romero R; Castro D; Lamana A; Mellado M; González-Álvaro I; Gomariz RP
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
